Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer

Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer

Wan-Ling Liu,1– 4,* Yong-Qu Zhang,1– 5,* Xiang-Jie Luo,6 Yuan-Yuan Zhu,1– 4 Liang Song,7 Zi-He Ming,1– 4 Li-Xin Zhang,1– 4 Meng-Jun Li,1– 4 Rui-Chan Lv,8 Guo-Jun Zhang,1– 4,9,* Min Chen2– 4,* 1Department of Breast-Thyroid-Surgery and Cancer Center, Xiang’an Hospital o...

Full description

Bibliographic Details
Main Authors: Liu WL, Zhang YQ, Luo XJ, Zhu YY, Song L, Ming ZH, Zhang LX, Li MJ, Lv RC, Zhang GJ, Chen M
Format: Article
Language:English
Published: Dove Medical Press 2023-09-01
Series:International Journal of Nanomedicine
Subjects:
dual-modal imaging
triple-negative breast cancer
immune-checkpoint blocking therapy
programmed cell death protein ligand-1
monitoring therapeutic response.
Online Access:https://www.dovepress.com/novel-dual-mode-nir-iimri-nanoprobe-targeting-pd-l1-accurately-evaluat-peer-reviewed-fulltext-article-IJN

Internet

https://www.dovepress.com/novel-dual-mode-nir-iimri-nanoprobe-targeting-pd-l1-accurately-evaluat-peer-reviewed-fulltext-article-IJN

Similar Items